Samsung Biologics to Acquire GSK’s US Drug Manufacturing Site for $280 Million

Samsung Biologics has agreed to acquire a drug production facility in the United States from GlaxoSmithKline, as the contract drug maker looks to expand capacity and strengthen its presence in its largest end market, as per Reuters. 

Transaction Details 

According to Reuters, Samsung Biologics will purchase the facility for $280 million through its US unit, Samsung Biologics America.  

The site is located in Rockville, Maryland, and is currently operated by Human Genome Sciences, a GSK subsidiary. The transaction is expected to be completed by the end of the first quarter of 2026. 

Manufacturing Capacity 

The facility has an existing drug substance production capacity of around 60,000 litres. Samsung Biologics said it plans to invest further to expand output and upgrade manufacturing capabilities at the site to support long-term customer demand. 

Strategic Rationale 

The acquisition represents Samsung Biologics’ first manufacturing base in the US, allowing it to be closer to key pharmaceutical clients.  

The company said demand for biologics manufacturing continues to grow, particularly from global drugmakers seeking stable and scalable supply chains. 

Read More: JP Morgan Plans to Build Asia’s Largest Global Capability Centre in Mumbai! 

Conclusion 

The US facility acquisition underscores Samsung Biologics’ strategy to expand global production capacity and deepen its presence in major pharmaceutical markets as competition in contract manufacturing intensifies. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.